AOC 1001
Avidity Biosciences
['in-person']
join us this week at #aanam as we share topline data from our phase 1/2 marina trial in (#dm1) presented by dr. nicholas johnson, followed by an in-person and webcast investor and analyst series event. to register, visit: 
Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies to address the unmet needs of the rare disease community.